A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Inclusion Criteria:

- adult patients, 18-75 years age;

- type 2 diabetes receiving pioglitazone (>= 30 mg/day) and metformin (>= 1500 mg/day)
for at least 12 weeks prior to screening;

- HbA1c >=7.0% and <=10.0% at screening;

- BMI >= 25 (>23 for Asians) and <=45 kg/m2 at screening;

- stable weight +/-5% for at least 12 weeks prior to screening.

Exclusion Criteria:

- history of type 1 diabetes mellitus or acute metabolic diabetic complications such as
ketoacidosis or hyperosmolar coma in the previous 6 months;

- evidence of clinically significant diabetic complications;

- clinically symptomatic gastrointestinal disease;

- myocardial infarction, coronary artery bypass surgery, post-transplantation
cardiomyopathy or stroke within the previous 6 months;

- known hemoglobinopathy or chronic anemia.